Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus DENDRID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus DENDRID.
ADEFOVIR DIPIVOXIL vs DENDRID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
10 mg orally once daily on an empty stomach.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Category C
Category C
Antiviral
Antiviral